- <![CDATA[FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML]]><![CDATA[The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.]]>onclive · 2mo ago↗ source
- <![CDATA[FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma]]><![CDATA[The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.]]>onclive · 2mo ago↗ source
- Takeda to target 4,500 jobs as incoming CEO continues restructuringTakeda will cut roughly 9% of its workforce over the next fiscal year as the next CEO puts her stamp on a yearslong restructuring. About 4,500 roles will be affected, the company said Wednesday i…